RT Journal Article
SR Electronic
T1 Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4325
OP 4328
DO 10.21873/anticanres.13598
VO 39
IS 8
A1 AKITAKE, MASAKAZU
A1 YAMAGUCHI, AKITO
A1 SHIOTA, MASAKI
A1 IMADA, KENJIRO
A1 TATSUGAMI, KATSUNORI
A1 YOKOMIZO, AKIRA
A1 NAITO, SEIJI
A1 ETO, MASATOSHI
YR 2019
UL http://ar.iiarjournals.org/content/39/8/4325.abstract
AB Background/Aim: The significance of second transurethral resection (TUR), and identification of predictive factors for residual cancer remain unrevealed. This study aimed to find residual cancer and up-staging rates, as well as predictive factors for residual cancer, in patients who undergo second TUR for non-muscle-invasive bladder cancer (NMIBC). Patients and Methods: Patients who underwent second TURs for NMIBC between 2015 and 2017, were included in the study and their clinicopathological characteristics were analyzed for predictors of residual cancer. Results: Among 143 Japanese patients whose tumors were initially diagnosed as high-risk NMIBC, residual cancers detected at second TURs were, Tis: n=22 (15.4%), Ta: n=15 (10.5%) and T1: n=29 (20.3%). No patients showed up-staging from NMIBC to MIBC. The presence of carcinoma-in situ at initial TUR was an independent risk factor for any residual cancer (Tis, Ta and T1), non-flat residual cancer (Ta and T1), and flat residual cancer (Tis). Conclusion: The presence of carcinoma-in situ is suggested to be an independent predictor of residual cancer. This may help guide decisions to perform second TUR.